Gene therapy vectors harboring AFP regulatory sequences. Preparation of an adenoviral vector.
Gene therapy for hepatocellular carcinoma (HCC) may be achieved by introducing a therapeutic gene under the control of transcriptional regulatory sequences of the alpha-fetoprotein (AFP) gene. Transcription of the human AFP gene is controlled positively by the promoter and the enhancer and negatively by the silencer. The AFP promoter is a 200-bp region immediately upstream of the AFP gene, and the enhancer is present between 3 and 4.9 kb upstream of the transcription initiation site. Two silencer regions have been identified upstream of the gene, one at -0.31 kb and the other at -1.75 kb. To achieve specific killing of HCC, adenoviral vectors carrying AFP regulatory sequences have been constructed. In this article, we describe the details of the preparation of an adenoviral vector designed to express the herpes simplex virus thymidine kinase gene under the control of the 4.9-kb AFP 5'-regulatory sequence. Treatment with this viral vector followed by ganciclovir resulted in specific killing of AFP-positive HCC transplanted in nude mice. Other viral vectors containing AFP-regulatory sequences are also discussed.
Kaneko
S
S
First Dept. Internal Medicine, Kanazawa University, Takara-machi 13-1, Kanazawa, Ishikawa 920, Japan. skaneko@med.m.kanazawa-4.ac.jp
Tamaoki
T
T
D015316:Genetic Therapy; D005822:Genetic Vectors; D011994:Recombinant Proteins / Q000235:genetics; D012045:Regulatory Sequences, Nucleic Acid; D000509:alpha-Fetoproteins / Q000235:genetics*
D011994:Recombinant Proteins; D000509:alpha-Fetoproteins